Cold exposure metabolism starts with a stronger baseline. Learn how glucose, lipids, body composition, and recovery shape long-term resilience.
Video·Peter Attia MD·9 min read·September 18, 2023
Metabolic health is more than weight or a single annual blood test. This outline follows Peter Attia’s framework for defining metabolic syndrome, understanding its wider disease risk, and looking beyond BMI toward clearer markers of resilience.
The Metabolic Baseline
Metabolic health sits at the center of how we age. In Peter Attia’s framework, metabolic disease is one of the four major diseases of aging, alongside cardiovascular disease, cancer, and neurodegenerative disease. It does not begin at one fixed line. It moves across a range, from obesity through type 2 diabetes, with many quieter states in between.
That range matters because diagnosis arrives late. A person can avoid the formal label of diabetes and still carry signals that show strain: higher glucose, higher triglycerides, lower HDL cholesterol, elevated blood pressure, or excess visceral fat. The body often speaks before the chart names a disease. Metabolic health asks us to listen earlier.
The higher standard is not simply avoiding pathology. It is building a body that handles fuel with precision, maintains stable markers, and preserves capacity over time. This is a more deliberate bar. It shifts the question from “Am I sick?” to “How resilient is my system under ordinary life?”
We favor that question because it gives you agency. Metabolic health is not an abstract category held inside a lab report. It is an individual, measurable state that reflects how your body responds to food, exercise, sleep, stress, and recovery. The numbers are not identity; they are feedback.
Attia’s view also moves beyond the annual physical as the full picture. Standard blood work has value, but it often shows only the easiest markers to collect. A more complete protocol looks at blood biomarkers, body composition, glucose handling, imaging, and functional performance. Each layer adds context.
This is where the practice becomes precise. You are not chasing perfection. You are establishing a baseline, observing trends, and raising the quality of your decisions. When the baseline is clear, recovery becomes more than rest. It becomes a disciplined return to equilibrium.
hey everyone welcome to the drive podcast I'm your host Peter attia Peter welcome to another AMA how you doing good thanks for having me doing good thanks for having me yeah so today's AMA we're really going yeah so today's AMA we're really going to focus on metabolic health so I think to focus on metabolic health so I think a lot of people are familiar with this a lot of people are familiar with this term you call the four horsemen which term you call the four horsemen which are the four major diseases of Aging are the four major diseases of Aging that includes cardiovascular disease that includes cardiovascular disease cancer neurogenitive disease and then cancer neurogenitive disease and then metabolic disease which is really a metabolic disease which is really a range of conditions kind of from obesity range of conditions kind of from obesity all the way to type 2 diabetes and we all the way to type 2 diabetes and we haven't covered it on recent amas haven't covered it on recent amas that closely and so what we wanted to do that closely and so what we wanted to do was gather all the questions that have was gather all the questions that have come in on that and then put them into come in on that and then put them into today's AMA so we're going to hopefully today's AMA so we're going to hopefully get to as many as we can but this will get to as many as we can but this will include like what is metabolic disease include like what is metabolic disease and how do you define it how it feeds and how do you define it how it feeds the other three main Horsemen and how it
the other three main Horsemen and how it can cause problems for people and then can cause problems for people and then really look at the metrics that you look really look at the metrics that you look at with your patients who understand on at with your patients who understand on an individual level where they're at an individual level where they're at metabolic-wise and so I think a lot of metabolic-wise and so I think a lot of people will look at metabolic Health people will look at metabolic Health from simple blood metrics such as hba1c from simple blood metrics such as hba1c or things that they can get with a or things that they can get with a typical annual physical but I know with typical annual physical but I know with you and your patients you look at a lot you and your patients you look at a lot of other things and we're going to get of other things and we're going to get into those details today which is you into those details today which is you know what are those things what do you know what are those things what do you like to see and ultimately what can they like to see and ultimately what can they tell people about their metabolic health tell people about their metabolic health and then we'll end the AMA looking at and then we'll end the AMA looking at kind of what are the lifestyle kind of what are the lifestyle interventions that people can use to interventions that people can use to help improve their metabolic health and help improve their metabolic health and this will look at nutrition sleep and this will look at nutrition sleep and exercise so we have a lot to get to so exercise so we have a lot to get to so with all that said anything you want to with all that said anything you want to add before we get started uh no I mean I add before we get started uh no I mean I just think we're going to structure this just think we're going to structure this discussion by discussion by you know probably spending a bit of time you know probably spending a bit of time talking about the nuanced ways in which talking about the nuanced ways in which you could Define or identify a person you could Define or identify a person who's not metabolically healthy
who's not metabolically healthy um and and we'll we'll come up with a um and and we'll we'll come up with a very high bar for that on what you know very high bar for that on what you know real metabolic Health looks like real metabolic Health looks like um and then as you said we'll we'll talk um and then as you said we'll we'll talk about okay what do you do about it if about okay what do you do about it if you're in this situation because most you're in this situation because most people listening to this uh myself people listening to this uh myself included frankly will always have an included frankly will always have an area in which they could improve area in which they could improve let's start with a little bit primer on let's start with a little bit primer on metabolic disease and how it can feed metabolic disease and how it can feed into the other three Horsemen which is into the other three Horsemen which is cardiovascular disease cancer cardiovascular disease cancer neurogenitor disease so to do this I neurogenitor disease so to do this I think we need to kind of Define think we need to kind of Define metabolic disease or metabolic syndrome metabolic disease or metabolic syndrome and there look at how that feeds those and there look at how that feeds those other diseases other diseases I think a bit of historical context is I think a bit of historical context is is helpful here there was a a very is helpful here there was a a very famous uh remarkable endocrinologist by famous uh remarkable endocrinologist by the name of Jerry Riven uh definitely the name of Jerry Riven uh definitely one of the regrets I have is not having one of the regrets I have is not having interviewed Jerry for the podcast before interviewed Jerry for the podcast before he passed away because I did know him he passed away because I did know him and I'd met him several times and I'd met him several times um and um and um Jerry uh was at Stanford for most of
um Jerry uh was at Stanford for most of his career his career in the 1980s made an observation which in the 1980s made an observation which was that where the following five was that where the following five um signs went so too did cardiovascular um signs went so too did cardiovascular disease cancer neurodegenerative disease disease cancer neurodegenerative disease he identified these five signs which he identified these five signs which we'll review in a second and he referred we'll review in a second and he referred to it as Syndrome X so he said look when to it as Syndrome X so he said look when people have trunkle obesity elevated people have trunkle obesity elevated triglycerides depressed HDL cholesterol triglycerides depressed HDL cholesterol elevated blood pressure elevated blood pressure and elevated glucose levels and elevated glucose levels uh this thing we're going to call uh this thing we're going to call Syndrome X and it seems to be a Syndrome X and it seems to be a remarkable predictor of all of these remarkable predictor of all of these chronic diseases of Aging chronic diseases of Aging uh for the sake of time I'm not going to uh for the sake of time I'm not going to go through the entire history of this go through the entire history of this but what changed was that that but what changed was that that terminology became syndrome exit terminology became syndrome exit referred it became now metabolic referred it became now metabolic syndrome and and now we have some syndrome and and now we have some numbers that go with those things so numbers that go with those things so um you know but many people are probably
um you know but many people are probably familiar with these but you know we're familiar with these but you know we're now defining truncal obesity as a waste now defining truncal obesity as a waste circumference of more than 40 inches in circumference of more than 40 inches in men more than 35 inches in women we're men more than 35 inches in women we're defining elevated triglycerides as over defining elevated triglycerides as over 150 milligrams per deciliter we're 150 milligrams per deciliter we're defining low HDL cholesterol is below 40 defining low HDL cholesterol is below 40 milligrams per deciliter in men below 50 milligrams per deciliter in men below 50 in women in women we Define elevated blood pressure as we Define elevated blood pressure as above 130 over 85 or taking medication above 130 over 85 or taking medication for high blood pressure over 120 over for high blood pressure over 120 over 80. and fasting glucose is greater than 80. and fasting glucose is greater than 100 milligrams per deciliter and the the 100 milligrams per deciliter and the the syndrome is defined as having three or syndrome is defined as having three or more of these so more of these so um um I won't suggest that this is the best I won't suggest that this is the best way to evaluate metabolic health I think way to evaluate metabolic health I think there are many more nuances that we're there are many more nuances that we're going to go into going to go into but at a minimum I think everybody but at a minimum I think everybody should know where they stand on those should know where they stand on those things and by the way even though things and by the way even though metabolic syndrome is defined as having metabolic syndrome is defined as having three or more of those having one of three or more of those having one of those is still worse than having none those is still worse than having none having two is worse than having one Etc
having two is worse than having one Etc so in an Ideal World you wouldn't want so in an Ideal World you wouldn't want to have any of these things to have any of these things no I think that's good to kind of set no I think that's good to kind of set that Baseline there and so the next that Baseline there and so the next question is then how does metabolic question is then how does metabolic syndrome kind of feed the other horsemen syndrome kind of feed the other horsemen and those other diseases and those other diseases we could spend the entirety of this AMA we could spend the entirety of this AMA going through the literature on this going through the literature on this it's uh it's so voluminous and so it's uh it's so voluminous and so uh one-sided that I don't think it's uh one-sided that I don't think it's particularly interesting so I'll particularly interesting so I'll probably just touch on a couple of high probably just touch on a couple of high points and we'll leave all the details points and we'll leave all the details in the show notes in the show notes but if you look at all the meta-analyzes but if you look at all the meta-analyzes of all-cause mortality cardiovascular of all-cause mortality cardiovascular mortality cancer mortality cancer mortality cancer mortality cancer incidence dementia incidents all of incidence dementia incidents all of these things all point in the same these things all point in the same direction once you have metabolic direction once you have metabolic syndrome you're at an increased risk of syndrome you're at an increased risk of everything you're in your risk of everything you're in your risk of cardiovascular disease goes up by 135 cardiovascular disease goes up by 135 percent your cardiovascular mortality
percent your cardiovascular mortality goes up by 140 percent your all-cause goes up by 140 percent your all-cause mortality is up by 58 your Mi risk 99 mortality is up by 58 your Mi risk 99 it's basically a doubling your stroke it's basically a doubling your stroke 127 percent when you look at cancer it's 127 percent when you look at cancer it's a 56 percent increase in age-adjusted a 56 percent increase in age-adjusted risk of cancer mortality if you have met risk of cancer mortality if you have met sin in particular there are a handful of sin in particular there are a handful of cancers that seem especially impacted by cancers that seem especially impacted by the this so endometrial cancer seven the this so endometrial cancer seven times as likely esophageal cancer almost times as likely esophageal cancer almost five times as likely gastric cancer five times as likely gastric cancer twice as likely liver kidney twice as twice as likely liver kidney twice as likely so there are a handful of cancers likely so there are a handful of cancers that that even appear to be that that even appear to be especially exacerbated by metabolic especially exacerbated by metabolic syndrome or by obesity and overweight syndrome or by obesity and overweight and so and so um you know I think most people um you know I think most people understand that smoking is an enormous understand that smoking is an enormous driver of risk for cancer it is it driver of risk for cancer it is it Remains the number one environmental Remains the number one environmental trigger of cancer but obesity is number trigger of cancer but obesity is number two and if you look more closely at the
two and if you look more closely at the data it's really metabolic syndrome data it's really metabolic syndrome which obviously overlaps a lot with which obviously overlaps a lot with obesity if we turn our attention then to obesity if we turn our attention then to neurodegenerative diseases and we'll neurodegenerative diseases and we'll start with Parkinson's disease the start with Parkinson's disease the largest meta-analysis on this study largest meta-analysis on this study suggests about a 24 percent higher risk suggests about a 24 percent higher risk of Parkinson's disease in those with of Parkinson's disease in those with metabolic syndrome compared to those metabolic syndrome compared to those without it also appears to be graded without it also appears to be graded again just as we see in atherosclerosis again just as we see in atherosclerosis we see that having you know three of the we see that having you know three of the risk factors for metabolic syndrome is a risk factors for metabolic syndrome is a 31 percent higher risk of Parkinson's 31 percent higher risk of Parkinson's disease while having all five 66 percent disease while having all five 66 percent increase in Risk when it comes to to increase in Risk when it comes to to Alzheimer's disease it's about a 10 Alzheimer's disease it's about a 10 percent increase in Alzheimer's disease percent increase in Alzheimer's disease for those with met sin and what's for those with met sin and what's interesting at least in the interesting at least in the meta-analysis we we looked at was meta-analysis we we looked at was because I thought that was actually a because I thought that was actually a surprisingly low number I thought that surprisingly low number I thought that having metabolic syndrome only having metabolic syndrome only increasing Alzheimer's Disease by 10
increasing Alzheimer's Disease by 10 percent uh struck me as as low but if percent uh struck me as as low but if you look more closely at the data you'll you look more closely at the data you'll realize that there actually appears to realize that there actually appears to be a protective role in the abdominal be a protective role in the abdominal obesity risk factor so when you do the obesity risk factor so when you do the analysis by looking at each of the analysis by looking at each of the metrics of medicine individually metrics of medicine individually there's about a 16 reduction in there's about a 16 reduction in um in in the Ben quote unquote um in in the Ben quote unquote protective benefits of abdominal obesity protective benefits of abdominal obesity now this is likely due to reverse now this is likely due to reverse causality causality um so meaning having Nets having um so meaning having Nets having Alzheimer's disease is more likely to Alzheimer's disease is more likely to lead to abdominal obesity but lead to abdominal obesity but nevertheless I think that's why those nevertheless I think that's why those numbers don't look as big numbers don't look as big when you look at all forms of dementia when you look at all forms of dementia because remember Alzheimer's disease is because remember Alzheimer's disease is the most prevalent form of dementia but the most prevalent form of dementia but there are many forms of dementia that there are many forms of dementia that are not Alzheimer's there's vascular are not Alzheimer's there's vascular dementia Lewy Body dementia frontal dementia Lewy Body dementia frontal temporal dementia so all all comers you temporal dementia so all all comers you know vascular dementia is about a 37 know vascular dementia is about a 37 percent increase in Risk yeah so I think percent increase in Risk yeah so I think that's a really good and kind of quick
that's a really good and kind of quick overview of how metabolic syndrome can overview of how metabolic syndrome can feed into the other diseases and like feed into the other diseases and like you said we'll have a lot more detail on you said we'll have a lot more detail on the show now it's because the reality is the show now it's because the reality is we just don't want to spend the entire we just don't want to spend the entire AMA on that because I think at this AMA on that because I think at this point people kind of understand okay point people kind of understand okay this is an important thing to care about this is an important thing to care about and I should understand this for myself and I should understand this for myself and so the next section then starts to and so the next section then starts to get to how do you identify Beyond just get to how do you identify Beyond just the metabolic syndrome what are some the metabolic syndrome what are some other metrics that someone can look at other metrics that someone can look at to know their kind of specific metabolic to know their kind of specific metabolic health and one question that we get a health and one question that we get a lot which is just starting at the basics lot which is just starting at the basics is how helpful is body weight nbmi to is how helpful is body weight nbmi to actually understand someone's metabolic actually understand someone's metabolic Health it's such a crude Tool uh it's Health it's such a crude Tool uh it's it's understandable why body weight and it's understandable why body weight and BMI are used as health indicators at the BMI are used as health indicators at the population level you're you know you're population level you're you know you're stuck with things that are very simple stuck with things that are very simple and reliable
and reliable um but I think you know if you hold up um but I think you know if you hold up the figure from I don't remember which the figure from I don't remember which chapter in in outlive it's from but it's chapter in in outlive it's from but it's uh it's it's from and you know an uh it's it's from and you know an analysis that analysis that um I did to basically try to disentangle um I did to basically try to disentangle obesity and metabolic syndrome so if you obesity and metabolic syndrome so if you if you take a look at that figure and by if you take a look at that figure and by the way these These are data that came the way these These are data that came from you know the NIH from you know the NIH um and um and um I think these turn out to be kind of um I think these turn out to be kind of conservative numbers but you know conservative numbers but you know conservatively speaking you have at the conservatively speaking you have at the time of this analysis 2021 108 million time of this analysis 2021 108 million obese people in the United States these obese people in the United States these are adults and 150 million non-obese so are adults and 150 million non-obese so obese being defined as a BMI over 30. obese being defined as a BMI over 30. um now if you look at the people who are um now if you look at the people who are obese and have metabolic syndrome it's obese and have metabolic syndrome it's 62 percent of the obese have metabolic 62 percent of the obese have metabolic syndrome so that's 67 million people uh
syndrome so that's 67 million people uh are obese with metabolic syndrome uh are obese with metabolic syndrome uh conversely if you look at the 150 conversely if you look at the 150 million people who are not obese uh 22 million people who are not obese uh 22 of those people have metabolic syndrome of those people have metabolic syndrome for a 33 million and so what you can see for a 33 million and so what you can see is that you've got a hundred million is that you've got a hundred million people uh and again I think that's a people uh and again I think that's a very conservative estimate other others very conservative estimate other others have come up with numbers as high as 125 have come up with numbers as high as 125 million but call it 100 million people million but call it 100 million people with metabolic syndrome in the U.S but with metabolic syndrome in the U.S but what I think is most interesting is a what I think is most interesting is a third of them are not obese and so third of them are not obese and so you know you know if you think about all the things that if you think about all the things that we look at in our patients we look at in our patients and all of the metrics we have on them I and all of the metrics we have on them I can just tell you I don't know the BMI can just tell you I don't know the BMI of one of my patients and I don't care of one of my patients and I don't care um because I'm not trying to practice um because I'm not trying to practice medicine on a population basis so medicine on a population basis so um you know I don't even know my BMI I um you know I don't even know my BMI I know I know I'm overweight by BMI but know I know I'm overweight by BMI but you know it's not something that we're you know it's not something that we're going to manage so look I mean going to manage so look I mean ultimately BMI just it's not that ultimately BMI just it's not that helpful right it doesn't account for
helpful right it doesn't account for body composition it doesn't account for body composition it doesn't account for insulin sensitivity in any way shape or insulin sensitivity in any way shape or form form um you know so so we just we just don't um you know so so we just we just don't rely on it at all we'll do dexa scans rely on it at all we'll do dexa scans we'll we'll get into those details but we'll we'll get into those details but we don't care about BMI it's a good we don't care about BMI it's a good intro to this next section which is what intro to this next section which is what are those metrics that you use with your are those metrics that you use with your patients to understand their metabolic patients to understand their metabolic Health at an individual level and so I Health at an individual level and so I think what might be helpful for people think what might be helpful for people is if you just kind of run through what is if you just kind of run through what those are and then what we'll do after those are and then what we'll do after is we'll double click on each of them is we'll double click on each of them some of them going into more detail than some of them going into more detail than others depending on past content but I others depending on past content but I think it'd just be kind of helpful for think it'd just be kind of helpful for people just to hear that full list quick people just to hear that full list quick yeah I mean we kind of organized them as yeah I mean we kind of organized them as um you know functional tests Imaging um you know functional tests Imaging tests you know typical or regular tests you know typical or regular biomarkers maybe some special tests and biomarkers maybe some special tests and and then we'll even talk about things and then we'll even talk about things that are only done in research that we that are only done in research that we don't do but would you might see these don't do but would you might see these things show up in in papers that you're things show up in in papers that you're reading so on the kind of regular slash reading so on the kind of regular slash traditional you know blood-based traditional you know blood-based biomarkers we we look at uric acid
biomarkers we we look at uric acid homocysteine triglycerides HDL homocysteine triglycerides HDL cholesterol fasting glucose insulin cholesterol fasting glucose insulin hemoglobin A1c and and liver function hemoglobin A1c and and liver function tests tests um you know I'd say one of the less um you know I'd say one of the less common things that we do look at is common things that we do look at is resting and fasting lactate levels resting and fasting lactate levels um and obviously lactate performance in um and obviously lactate performance in response to exercise so that's also kind response to exercise so that's also kind of a functional test when it comes to of a functional test when it comes to the functional stuff though we're the functional stuff though we're looking at zone two output we look at looking at zone two output we look at cpat testing so effectively the the you cpat testing so effectively the the you know oxygen utilization CO2 production know oxygen utilization CO2 production under stress oral glucose tolerance test under stress oral glucose tolerance test so again I don't put that down as a so again I don't put that down as a traditional blood-based biomarker traditional blood-based biomarker because I think of that as really a because I think of that as really a functional test although of course it functional test although of course it relies on these biomarkers it's relies on these biomarkers it's continuous glucose monitoring and then continuous glucose monitoring and then whole body respiratory Suites we whole body respiratory Suites we personally don't do that in our practice personally don't do that in our practice we do all the others but we don't do the we do all the others but we don't do the whole body respiratory stuff but you can whole body respiratory stuff but you can do that to to obviously get a sense of do that to to obviously get a sense of respiratory quotient
respiratory quotient Imaging studies can be really valuable Imaging studies can be really valuable here so dexa scans which are measuring here so dexa scans which are measuring visceral adipose tissue and also visceral adipose tissue and also measuring muscle mass body fat which is measuring muscle mass body fat which is certainly more relevant than body weight certainly more relevant than body weight or BMI or BMI we certainly would never rely on CT we certainly would never rely on CT scans for for looking at visceral fat scans for for looking at visceral fat although one could do it and you do get although one could do it and you do get it with MRI if you have the right it with MRI if you have the right software liver ultrasound along with software liver ultrasound along with algorithms that combine liver ultrasound algorithms that combine liver ultrasound with blood tests to look at fibrosis with blood tests to look at fibrosis scores become very important as you want scores become very important as you want to understand the prevalence of fatty to understand the prevalence of fatty liver disease and though we don't do liver disease and though we don't do this you might see this kind of stuff in this you might see this kind of stuff in in research studies and it's it's very in research studies and it's it's very interesting stuff so you could you could interesting stuff so you could you could look at look at c16 saturated fatty acids this gives you c16 saturated fatty acids this gives you a sense of fat metabolism and of course a sense of fat metabolism and of course intramuscular biopsies will give you a intramuscular biopsies will give you a great sense of how much fat is being great sense of how much fat is being stored in a muscle and that can be
stored in a muscle and that can be obviously relevant for insulin obviously relevant for insulin resistance and it's obviously resistance and it's obviously mechanistically important as well as we mechanistically important as well as we discussed in the Jerry Shulman podcast discussed in the Jerry Shulman podcast again those aren't things that we're again those aren't things that we're doing in clinical practice doing in clinical practice I think it's really helpful for people I think it's really helpful for people just to kind of hear that whole list and just to kind of hear that whole list and now we'll jump into kind of each of now we'll jump into kind of each of those into a little more detail some those into a little more detail some more than others and we'll kind of look more than others and we'll kind of look at what trends you're looking for what at what trends you're looking for what are the ranges you'd like to see and are the ranges you'd like to see and then ultimately it will lead to the then ultimately it will lead to the second section of this which is how do second section of this which is how do you improve those various metrics so why you improve those various metrics so why don't we start with some of the more don't we start with some of the more regular or traditional biomarker tests regular or traditional biomarker tests that most people will probably get at that most people will probably get at any type of physical screening annual any type of physical screening annual exam they go to can you kind of walk exam they go to can you kind of walk through what those are and what metrics through what those are and what metrics you're hoping to see within your you're hoping to see within your patients patients foreign foreign thank you for listening to today's sneak thank you for listening to today's sneak peek AMA episode of the drive if you're peek AMA episode of the drive if you're interested in hearing the complete interested in hearing the complete version of this AMA you'll want to version of this AMA you'll want to become a premium member it's extremely
become a premium member it's extremely important to me to provide all of this important to me to provide all of this content without relying on paid ads to content without relying on paid ads to do this our work is made entirely do this our work is made entirely possible by our members and in return we possible by our members and in return we offer exclusive member-only content and offer exclusive member-only content and benefits above and beyond what is benefits above and beyond what is available for free so if you want to available for free so if you want to take your knowledge of this space to the take your knowledge of this space to the next level it's our goal to ensure next level it's our goal to ensure members get back much more than the members get back much more than the price of a subscription premium price of a subscription premium membership includes several benefits membership includes several benefits first comprehensive podcast show notes first comprehensive podcast show notes that detail every topic paper person and that detail every topic paper person and thing that we discuss in each episode thing that we discuss in each episode and the word on the street is nobody's and the word on the street is nobody's show notes rival hours show notes rival hours second monthly ask me anything or AMA second monthly ask me anything or AMA episodes these episodes are comprised of episodes these episodes are comprised of detailed responses to subscriber detailed responses to subscriber questions typically focused on a single questions typically focused on a single topic and are designed to offer a great topic and are designed to offer a great deal of clarity and detail on topics of deal of clarity and detail on topics of special interest to our members you'll special interest to our members you'll also get access to the show notes for also get access to the show notes for these episodes of course these episodes of course third delivery of our premium newsletter
third delivery of our premium newsletter which is put together by our dedicated which is put together by our dedicated team of research analysts this team of research analysts this newsletter covers a wide range of topics newsletter covers a wide range of topics related to longevity and provides much related to longevity and provides much more detail than our free Weekly more detail than our free Weekly Newsletter fourth access to our private Newsletter fourth access to our private podcast feed that provides you with podcast feed that provides you with access to every episode including amas access to every episode including amas Sans the Spiel you're listening to now Sans the Spiel you're listening to now and in your regular podcast feed and in your regular podcast feed fifth the qualities an additional fifth the qualities an additional member-only podcast we put together that member-only podcast we put together that serves as a highlight reel featuring the serves as a highlight reel featuring the best excerpts from previous episodes of best excerpts from previous episodes of the drive this is a great way to catch the drive this is a great way to catch up on previous episodes without having up on previous episodes without having to go back and listen to each one of to go back and listen to each one of them and finally other benefits that are them and finally other benefits that are added along the way added along the way if you want to learn more and access if you want to learn more and access these member-only benefits you can head these member-only benefits you can head over to Peter atteamd.com forward slash over to Peter atteamd.com forward slash subscribe you can also find me on subscribe you can also find me on YouTube Instagram and Twitter all with YouTube Instagram and Twitter all with the handle Peter attia MD you can also the handle Peter attia MD you can also leave us review on Apple podcasts or leave us review on Apple podcasts or whatever podcast player you use this
whatever podcast player you use this podcast is for General informational podcast is for General informational purposes only and does not constitute purposes only and does not constitute the practice of medicine nursing or the practice of medicine nursing or other professional healthcare services other professional healthcare services including the giving of medical advice including the giving of medical advice no doctor-patient relationship is formed no doctor-patient relationship is formed the use of this information and the the use of this information and the materials linked to this podcast is at materials linked to this podcast is at the user's own risk the content on this the user's own risk the content on this podcast is not intended to be a podcast is not intended to be a substitute for professional medical substitute for professional medical advice diagnosis or treatment users advice diagnosis or treatment users should not disregard or delay in should not disregard or delay in obtaining medical advice from any obtaining medical advice from any medical condition they have and they medical condition they have and they should seek the assistance of their should seek the assistance of their Health Care Professionals for any such Health Care Professionals for any such conditions finally I take all conflicts conditions finally I take all conflicts of interest very seriously for all of my of interest very seriously for all of my disclosures and the companies I invest disclosures and the companies I invest in or advise please visit Peter in or advise please visit Peter attiumd.com forward slash about where I attiumd.com forward slash about where I keep an up-to-date and active list of keep an up-to-date and active list of all disclosures all disclosures thank you
Transcript auto-generated by YouTube. Verbatim — duplicates intentionally preserved.
From Syndrome X to Metabolic Syndrome
The modern definition of metabolic syndrome began with a pattern. In the 1980s, Stanford endocrinologist Jerry Reaven described a cluster of signs he called Syndrome X. The observation was simple and powerful: when these signs appeared together, chronic disease risk tended to follow. The pattern became too consistent to ignore.
Those signs are still the foundation today. They include excess waist circumference, elevated triglycerides, low HDL cholesterol, elevated blood pressure, and elevated fasting glucose. Together, they offer a practical view of metabolic strain. They are not the whole story, but they are a necessary starting point.
The current waist threshold is more than 40 inches in men and more than 35 inches in women. This marker is not about appearance. It is a rough proxy for central fat accumulation, which overlaps with metabolic dysfunction and carries different risk than weight distributed elsewhere.
Triglycerides are considered elevated above 150 milligrams per deciliter. HDL cholesterol is considered low below 40 milligrams per deciliter in men and below 50 milligrams per deciliter in women. These two markers give a window into lipid handling, a core part of how the body manages and stores energy.
Blood pressure enters the definition above 130 over 85, or when someone takes medication for high blood pressure. Fasting glucose enters above 100 milligrams per deciliter. These thresholds are familiar, but their importance deepens when they appear together. The cluster tells a stronger story than any one number alone.
Metabolic syndrome is formally defined by having three or more of the five signs. That definition matters because it creates a shared clinical language. It gives physicians and patients a clear frame for risk. It also prevents the conversation from becoming vague.
Still, the formal definition is not the same as an ideal target. One abnormal marker is not neutral. Two are worse than one. The best baseline is none of them, because each signal points to a system carrying more load than it needs to carry.
This is the distinction between disease classification and mastery. A diagnosis tells you when a threshold has been crossed. A protocol helps you act before that threshold becomes your normal. The earlier signal deserves attention, because adaptation begins with awareness.
having one of those is still worse than having none
Why Metabolic Health Shapes Longevity
Metabolic syndrome does not stay in one lane. It amplifies risk across the major chronic diseases of aging, including cardiovascular disease, cancer, and neurodegenerative disease. That breadth is what makes the baseline so important. A metabolic signal can become a longevity signal.
Attia points to a large and consistent body of research in which the direction is clear. With metabolic syndrome, cardiovascular disease risk rises by 135 percent, cardiovascular mortality rises by 140 percent, and all-cause mortality rises by 58 percent. Myocardial infarction risk rises by 99 percent, while stroke risk rises by 127 percent.
These numbers change the emotional weight of the topic. Metabolic health is not a narrow conversation about weight management or glucose alone. It is a conversation about keeping the vascular system protected and the body capable. The outcome people feel is capacity: more years with more function.
Cancer risk also moves in the wrong direction. Attia cites a 56 percent increase in age-adjusted cancer mortality among those with metabolic syndrome. Certain cancers appear especially affected, including endometrial cancer at seven times the likelihood, esophageal cancer at almost five times, gastric cancer at twice the likelihood, and liver and kidney cancers at twice the likelihood.
Obesity remains part of the picture, but the more precise lens is metabolic dysfunction. Smoking remains the leading environmental trigger of cancer; obesity is second. When the data are examined more closely, metabolic syndrome overlaps heavily with that risk. The visible body is only one signal.
The same pattern extends into the brain. A large meta-analysis links metabolic syndrome with about a 24 percent higher risk of Parkinson’s disease. The risk appears graded: three metabolic syndrome factors correspond with a 31 percent higher risk, while all five correspond with a 66 percent higher risk.
Dementia shows a similar concern, though the categories require care. Alzheimer’s disease shows about a 10 percent increase in the analysis discussed, a figure Attia notes as lower than expected. All forms of dementia tell a stronger story, with vascular dementia linked to about a 37 percent increase in risk.
The lesson is not fear. It is leverage. When one domain of health influences several others, improving that domain becomes a high-value act. Metabolic health is a quiet foundation; when it is strong, the whole structure has more room to endure.
Better Signals Than BMI
BMI has a place, but it is not a precise individual measure. It works best at the population level because it is simple, inexpensive, and easy to collect. Those strengths become limits in a personal protocol. A number built for broad surveillance cannot tell the full story of one body.
Attia’s analysis separates obesity from metabolic syndrome and makes the limitation clear. In the United States, he describes 108 million adults with obesity and 150 million adults without obesity. Among adults with obesity, 62 percent had metabolic syndrome, representing 67 million people.
The more revealing group is the non-obese population. Among 150 million adults without obesity, 22 percent had metabolic syndrome, representing 33 million people. In that conservative estimate, roughly one-third of Americans with metabolic syndrome were not obese. BMI would miss too much if used alone.
This is why body composition matters more than scale weight. Muscle mass, body fat, and visceral adipose tissue carry more meaning than height divided into weight. Insulin sensitivity matters as well, because two people with the same BMI can handle glucose very differently. The surface can look similar while the system behaves differently.
A stronger assessment uses tools that match the question. DEXA scans can measure visceral adipose tissue, muscle mass, and body fat with more relevance than BMI. Liver ultrasound, especially when paired with blood-based algorithms for fibrosis scores, can help assess fatty liver disease. Imaging adds structure to the story.
Blood markers remain essential, but they work best as part of a wider set. Attia lists uric acid, homocysteine, triglycerides, HDL cholesterol, fasting glucose, insulin, hemoglobin A1c, and liver function tests. Resting and fasting lactate can add another layer. Each marker earns its place when it informs action.
I don't know the BMI of one of my patients and I don't care
Functional testing completes the picture. Zone two output, CPET testing, oral glucose tolerance testing, and continuous glucose monitoring all show how the body performs under real demand. A lab value is a still frame. A functional test shows motion.
The future-facing edge is even more detailed. Lactate response to exercise, respiratory quotient from whole body respiratory suites, MRI-based visceral fat analysis, liver imaging, C16 saturated fatty acids, and intramuscular biopsies all appear in the broader discussion or research setting. Not every tool belongs in everyday practice, but they point toward the same principle: measure the system, not just the silhouette.
The goal is not to collect data for its own sake. The goal is clearer self-knowledge, followed by deliberate change. When you understand your metabolic state with precision, you can build a protocol around recovery, training, nutrition, and sleep. That is how resilience becomes measurable.
